Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897075 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis
A Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 99
- Enrollment target
NCT03897075: Completed Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
NCT03897075 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 99 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03897075, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 99 participants
- Enrollment target
Study Summary
Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
Primary Outcome
Primary Efficacy Endpoint
Interventions
- DRUG Placebo
- DRUG Tildrakizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2025-01-30 |
| Phase | Phase 3 |
What the finished NCT03897075 record still lists
NCT03897075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 99 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03897075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03897075 about?
NCT03897075 is a clinical study titled "Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis". Phase 3b study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Nail Psoriasis
What is the current status of trial NCT03897075?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 99 participants. The study started on 2021-05-13. Estimated completion is 2025-01-30.
What interventions are being tested in trial NCT03897075?
The interventions under investigation include: Placebo (DRUG), Tildrakizumab (DRUG).
Who is sponsoring clinical trial NCT03897075?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03897075's enrollment target sits among peer trials
99 1713th of 2000 higher than 287 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03965234 · 99 participants · Phase 1
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
- NCT04022616 · 99 participants
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
- NCT04042844 · 99 participants · Phase 2
A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)
- NCT04143724 · 99 participants · Phase 2
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI